V. Labonia

532 total citations
16 papers, 246 citations indexed

About

V. Labonia is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, V. Labonia has authored 16 papers receiving a total of 246 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in V. Labonia's work include Breast Cancer Treatment Studies (9 papers), Cancer Treatment and Pharmacology (8 papers) and Estrogen and related hormone effects (6 papers). V. Labonia is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), Cancer Treatment and Pharmacology (8 papers) and Estrogen and related hormone effects (6 papers). V. Labonia collaborates with scholars based in Italy and Malaysia. V. Labonia's co-authors include A. De Matteis, Giuseppe D’Aiuto, Francesco Nuzzo, Ermelinda De Maio, Emanuela Rossi, Gabriella Landi, Gerardo Botti, Carmen Pacilio, Adriano Gravina and Francesco Perrone and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

V. Labonia

16 papers receiving 240 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. Labonia Italy	8	169	126	81	47	35	16	246
John L. Hopper Australia	4	129 0.8×	62 0.5×	180 2.2×	28 0.6×	22 0.6×	5	308
Santiago González-Santiago Spain	9	107 0.6×	78 0.6×	114 1.4×	28 0.6×	18 0.5×	22	236
Chantal Perret Canada	10	122 0.7×	82 0.7×	189 2.3×	48 1.0×	32 0.9×	11	329
Þorvaldur Jónsson Iceland	6	129 0.8×	44 0.3×	74 0.9×	36 0.8×	11 0.3×	13	224
Pedro Emanuel Rubini Liedke Brazil	9	141 0.8×	73 0.6×	65 0.8×	76 1.6×	35 1.0×	22	250
Rosaria Cesaraccio Italy	10	139 0.8×	76 0.6×	30 0.4×	51 1.1×	11 0.3×	14	243
Elena Aguirre Spain	8	117 0.7×	63 0.5×	43 0.5×	68 1.4×	9 0.3×	22	183
László Landherr Hungary	8	122 0.7×	61 0.5×	34 0.4×	62 1.3×	5 0.1×	20	191
Anna H. Wu United States	5	67 0.4×	44 0.3×	82 1.0×	109 2.3×	10 0.3×	7	278
Ashley Woodson United States	9	76 0.4×	116 0.9×	113 1.4×	58 1.2×	13 0.4×	18	242

Countries citing papers authored by V. Labonia

Since Specialization

Citations

This map shows the geographic impact of V. Labonia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Labonia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Labonia more than expected).

Fields of papers citing papers by V. Labonia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Labonia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Labonia. The network helps show where V. Labonia may publish in the future.

Co-authorship network of co-authors of V. Labonia

This figure shows the co-authorship network connecting the top 25 collaborators of V. Labonia. A scholar is included among the top collaborators of V. Labonia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Labonia. V. Labonia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Nuzzo, Francesco, Alessandro Morabito, Adriano Gravina, et al.. (2011). Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer. 11(1). 75–75. 10 indexed citations

2.

Perrone, Francesca, Cristina Gallo, Secondo Lastoria, et al.. (2011). Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study.. Journal of Clinical Oncology. 29(15_suppl). 517–517. 2 indexed citations

3.

Rossi, Emanuela, Alessandro Morabito, Francesca Di Rella, et al.. (2009). Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial. Journal of Clinical Oncology. 27(19). 3192–3197. 63 indexed citations

4.

Morabito, Anna, Emanuela Rossi, Francesca Di Rella, et al.. (2009). Endocrine effects of adjuvant letrozole versus tamoxifen in hormone responsive postmenopausal early breast cancer patients: results from the HOBOE randomized trial.. Cancer Research. 69(2_Supplement). 1150–1150. 1 indexed citations

5.

Nuzzo, Francesco, Alessandro Morabito, Ermelinda De Maio, et al.. (2007). Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology. 66(2). 171–180. 20 indexed citations

6.

Nuzzo, Francesco, Federica Perrone, V. Labonia, et al.. (2007). 2034 POSTER Weekly docetaxel vs CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the ELDA trial. European Journal of Cancer Supplements. 5(4). 194–194. 1 indexed citations

7.

Rossi, Emanuela, Alessandro Morabito, Ermelinda De Maio, et al.. (2007). Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer. Journal of Clinical Oncology. 26(2). 264–270. 36 indexed citations

8.

Pacilio, Carmen, Alessandro Morabito, Francesco Nuzzo, et al.. (2006). Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. British Journal of Cancer. 94(9). 1233–1236. 21 indexed citations

9.

Maio, Ermelinda De, Adriano Gravina, Carmen Pacilio, et al.. (2005). Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer. 5(1). 30–30. 25 indexed citations

10.

Matteis, A. De, Francesco Nuzzo, Giuseppe D’Aiuto, et al.. (2002). Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. Cancer. 94(4). 895–901. 10 indexed citations

11.

Matteis, A. De, Francesco Nuzzo, Giuseppe D’Aiuto, et al.. (2002). Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. Cancer. 94(4). 895–901. 46 indexed citations

12.

Matteis, A. De, Marco Montella, V. Labonia, et al.. (1998). Multimodal Treatment Strategy for Locally Advanced Breast Cancer. Journal of Chemotherapy. 10(6). 476–483. 2 indexed citations

13.

Matteis, A. De, et al.. (1998). Hormonotherapy with goserelin depot after adjuvant chemotherapy in premenopausal women with early breast cancer: Is there any benefit?. European Journal of Cancer. 34. S44–S44. 5 indexed citations

14.

Matteis, A. De, Giuseppe D’Aiuto, Francesco Nuzzo, et al.. (1998). P16 Adjuvant Goserelin depot in premenopausal women with early breast cancer: Ovarian function, bone mineral density and survival. Preliminary data. European Journal of Cancer. 34. S18–S18. 1 indexed citations

15.

Thomas, R., Immacolata Capasso, A. De Matteis, et al.. (1998). Long term survival in elderly breast cancer patients treated with tamoxifen (TAM) alone vs surgery followed by TAM. European Journal of Cancer. 34. S126–S126. 1 indexed citations

16.

Esposito, Gennaro, N. Panza, Luigi Mansi, et al.. (1991). Evaluation of TAG-72 as a serum marker in ovarian and breast carcinoma.. PubMed. 34(2). 88–93. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact